nilotinib
Showing 1 - 25 of 252
Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)
Recruiting
- Metastatic Melanoma
- BRAF Gene Mutation
- Nilotinib 100mg
- +5 more
-
Lexington, KentuckyMarkey Cancer Center
Jul 22, 2022
Tumors Trial run by the NCI (Nilotinib and Paclitaxel)
Recruiting
- Neoplasms
- Nilotinib and Paclitaxel
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 19, 2023
Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial (Biopsy, Biospecimen Collection, Computed Tomography)
Not yet recruiting
- Metastatic Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Biopsy
- +5 more
- (no location specified)
Nov 8, 2022
Solid Tumors Trial run by the National Cancer Institute (NCI) (Nilotinib + Paclitaxel)
Recruiting
- Solid Tumors
- Nilotinib + Paclitaxel
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 24, 2022
Acute Lymphoblastic Leukemia (ALL) Trial (Nilotinib)
No longer available
- Acute Lymphoblastic Leukemia (ALL)
- Nilotinib
- (no location specified)
Aug 5, 2022
Peritoneal Carcinomatosis, Peritoneal Tumors, Ovarian Cancer Trial run by the National Cancer Institute (NCI) (Paclitaxel,
Not yet recruiting
- Peritoneal Carcinomatosis
- +7 more
- Paclitaxel
- Nilotinib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Trial (Asciminib, Nilotinib)
Not yet recruiting
- Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
- Asciminib
- Nilotinib
- (no location specified)
Jul 11, 2022
Chronic Myeloid Leukemia Trial in New York (Nilotinib)
Completed
- Chronic Myeloid Leukemia
- Nilotinib
-
New York, New YorkWeill Cornell Medical College
Mar 24, 2022
Chronic Myeloid Leukemia, Chronic Phase, Nilotinib Trial in Shenzhen (Nilotinib)
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- Nilotinib
- Nilotinib
-
Shenzhen, Guangdong, ChinaShenzhen Second People's Hospital
Mar 15, 2022
GIST and CML Trial in Worldwide (AMN107)
Active, not recruiting
- GIST and CML
- Nilotinib
-
Albany, New York
- +32 more
Oct 4, 2022
Chronic Myelogenous Leukemia Trial in Beirut (Nilotinib)
Recruiting
- Chronic Myelogenous Leukemia
- Nilotinib
-
Beirut, LebanonAmerican University of Beirut Medical Center
Feb 14, 2022
Gastrointestinal Stromal Tumors Trial in Worldwide (Nilotinib)
Active, not recruiting
- Gastrointestinal Stromal Tumors
- Nilotinib
-
HUS, Finland
- +6 more
Apr 19, 2022
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Trial in France (Nilotinib)
Completed
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Nilotinib
-
Angers, France
- +9 more
Aug 17, 2022
Alzheimer Trial (Nilotinib BE 84mg, Nilotinib BE 112 mg, Placebo)
Not yet recruiting
- Alzheimer Disease
- Nilotinib BE 84mg
- +2 more
- (no location specified)
Nov 30, 2021
Chordoma Trial in Boston (Nilotinib, Radiation therapy)
Active, not recruiting
- Chordoma
- Nilotinib
- Radiation therapy
-
Boston, MassachusettsMassachusetts General Hospital
Oct 27, 2021
Ataxia, Cerebellar, Ataxia, Progressive Trial in Seoul (Nilotinib)
Completed
- Ataxia, Cerebellar
- Ataxia, Progressive
- Nilotinib
-
Seoul, Korea, Republic ofSeoul National University Hospital
Sep 23, 2021
Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and
Completed
- Leukemia
- No Intervention
-
Cambridge, MassachusettsTakeda
Feb 28, 2023
Hypereosinophilic Syndrome (HES) Trial (Nilotinib)
No longer available
- Hypereosinophilic Syndrome (HES)
- Nilotinib
- (no location specified)
Sep 14, 2021
Chronic Phase Chronic Myeloid Leukemia Trial in Bruxelles (Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID)
Terminated
- Chronic Phase Chronic Myeloid Leukemia
- Ponatinib 30 mg QD
- +2 more
-
Bruxelles, BelgiumCliniques Universitaire Saint-Luc (Site 058)
Oct 28, 2021
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic
Recruiting
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jun 15, 2022
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor Trial in United States
Active, not recruiting
- Pigmented Villonodular Synovitis
- +2 more
- nilotinib
-
Santa Monica, California
- +6 more
Jan 31, 2022
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid Trial in Augusta, Milwaukee (Asciminib, Ascimininb +
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- +3 more
- Asciminib
- Ascimininb + Nilotinib
-
Augusta, Georgia
- +1 more
Jul 14, 2022
Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid
Recruiting
- CML-CP; Mutation;Suboptimal Response or Failure in TKI
- Flumatinib
- Nilotinib
-
Wuhan, Hubei, ChinaWeiming Li
May 31, 2021
Chronic Myeloid Leukemia Trial in Germany, Netherlands (TKI discontinuation, nilotinib)
Active, not recruiting
- Chronic Myeloid Leukemia
- TKI discontinuation
- nilotinib
-
Freiburg, Baden-Württemberg, Germany
- +14 more
Nov 4, 2021